Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-001672-55
    Sponsor's Protocol Code Number:MW2010-03-02
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-01-13
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2014-001672-55
    A.3Full title of the trial
    A multicenter, multinational, randomized, controlled, assessor blinded study, performed in subjects with thermal burns, to evaluate the efficacy and safety of NexoBrid compared to Gel Vehicle and compared to Standard of Care
    Studio multicentrico, internazionale, randomizzato, controllato, in cieco per i valutatori, condotto su soggetti con ustioni termiche per valutare l'efficacia e la sicurezza di NexoBrid rispetto a un veicolo in gel e al trattamento standard di cura (SOC)

    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A multicenter, multinational, randomized, controlled, assessor blinded study, performed in subjects with thermal burns, to evaluate the efficacy and safety of NexoBrid compared to Gel Vehicle and compared to Standard of Care
    Studio multicentrico, internazionale, randomizzato, controllato, in cieco per i valutatori, condotto su soggetti con ustioni termiche per valutare l'efficacia e la sicurezza di NexoBrid rispetto a un veicolo in gel e al trattamento standard di cura (SOC).
    A.3.2Name or abbreviated title of the trial where available
    A multicenter, multinational, randomized, controlled, assessor blinded study, performed in subjects
    Studio multicentrico, internazionale, randomizzato, controllato, in cieco per i valutatori, condotto
    A.4.1Sponsor's protocol code numberMW2010-03-02
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02148705
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMEDIWOUND LTD
    B.1.3.4CountryIsrael
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMediWound Ltd
    B.4.2CountryIsrael
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationLe¿n Research S.L
    B.5.2Functional name of contact pointCristina d'Altilia
    B.5.3 Address:
    B.5.3.1Street AddressC.rso Vittorio Emanuele II, 74
    B.5.3.2Town/ cityTorino
    B.5.3.3Post code10121
    B.5.3.4CountryItaly
    B.5.4Telephone number+39 3331173304
    B.5.5Fax number+34 987 216 243
    B.5.6E-mailcrdaltilia@leonresearch.es
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name NEXOBRID - 5 G-POLVERE E GEL PER GEL -USO CUTANEO-POLVERE:FLACONCINO (VETRO) GEL: FLACONE (VETRO)-POLV: 5 G GEL: 50 G - 1 FLACONCINO+1 FLACONE
    D.2.1.1.2Name of the Marketing Authorisation holderTEVA PHARMA GMBH
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/02/107
    D.3 Description of the IMP
    D.3.1Product nameNexoBrid
    D.3.2Product code D03BA03
    D.3.4Pharmaceutical form Cutaneous powder
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPCutaneous use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product Yes
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeMiscela di enzimi (Bromelina) estratti dall'ananas
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name NEXOBRID - - 2 G - POLVERE E GEL PER GEL - USO CUTANEO. - POLVERE:FLACONCINO (VETRO) GEL: FLACONE (VETRO) - POLVERE: 2 G GEL: 20 G - 1 FLACONCINO + 1 FLACONE
    D.2.1.1.2Name of the Marketing Authorisation holderTEVA PHARMA GMBH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/02/107
    D.3 Description of the IMP
    D.3.1Product nameNexoBrid
    D.3.2Product code D03BA03
    D.3.4Pharmaceutical form Cutaneous powder
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPCutaneous use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product Yes
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeMiscela di enzimi (Bromelina) estratti dall'Ananas
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboGel
    D.8.4Route of administration of the placeboTopical use (Noncurrent)
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    The study objective is to evaluate the efficacy and safety of NexoBrid in removing burn eschar in hospitalized subjects with thermal burns.
    Dimostrare l'efficacia e la sicurezza di NexoBrid nella rimozione dell'escara in pazienti ospedalizzati con ustioni termiche.
    E.1.1.1Medical condition in easily understood language
    Dead tissue of a burn wound has to be removed to promote healing of the wound.
    Tessuto morto di una ferita da ustione che deve essere rimosso per promuovere la guarigione della ferita.
    E.1.1.2Therapeutic area Diseases [C] - Injuries, poisonings, and occupational diseases [C21]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLT
    E.1.2Classification code 10043418
    E.1.2Term Thermal burns
    E.1.2System Organ Class 100000004863
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate the efficacy of enzymatic eschar removal with NexoBrid by providing complete eschar removal as compared with Gel Vehicle.
    Dimostrare l'efficacia della rimozione enzimatica dell'escara con NexoBrid fornendo una rimozione dell'escara completa rispetto al veicolo in gel.
    E.2.2Secondary objectives of the trial
    To demonstrate the efficacy of enzymatic eschar removal with NexoBrid by providing earlier complete eschar removal, reduction in patients¿ surgical burden and its related blood loss as compared to SOC,
    and to assess the safety of NexoBrid compared to SOC, including demonstration that treatment with NexoBrid does not cause an unacceptable level of harm on wound closure outcome and long term outcomes of cosmesis and function.
    Dimostrare l'efficacia della rimozione enzimatica dell'escara con NexoBrid fornendo una rimozione dell'escara completa pi¿ precoce e una riduzione del carico chirurgico per i pazienti e della relativa perdita ematica rispetto al trattamento SOC;
    Valutare la sicurezza di NexoBrid rispetto al trattamento SOC, ivi inclusa la dimostrazione che il trattamento con NexoBrid non causa un livello di danno inaccettabile sull'esito della cicatrizzazione della ferita e sugli esiti a lungo termine di estetica e funzionalit¿.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Inclusion Criteria- Patient level
    1. Males and females; = 18 years of age,
    2. Thermal burns caused by fire/flame, scalds or contact,
    3. Patient total burns area = 3% DPT and / or FT,
    4. Patient total burns area should be = 30% TBSA; SPT, DPT and/or FT in depth,
    5. Informed consent can be obtained within 84 hours of the burn injury,
    6. Patients who are willing and able to sign a written consent form.

    Inclusion Criteria – Wound level
    1. At least one wound (a continuous burn area) that is =0.5% TBSA (DPT and/or FT) (this minimal wound size should not include face, perineal or genital),
    All planned target wounds (TWs) should meet the following criteria:
    2. SPT areas that cannot be demarcated from DPT and FT areas should be less than 50% of the % TBSA of the TW
    3. Wound’s blisters can be removed/unroofed, as judged by the investigator.
    Criteri di inclusione - Livello paziente
    1. Uomini e donne di età = 18 anni;
    2. Ustioni termiche provocate da fuoco o fiamme, scottature o contatto;
    3. Area totale ustionata del paziente = 3% DPT e/o FT;
    4. Area totale ustionata del paziente = 30% della TBSA e di profondità SPT, DPT e/o FT;
    5. Consenso informato ottenuto entro 84 ore dalla lesione da ustione;
    6. Volontà e capacità del paziente di firmare un modulo di consenso scritto.
    Criteri di inclusione - Livello ferita
    1. Almeno una ferita (un'area ustionata continua) di dimensioni =0,5% di TBSA (DPT e/o FT) (questa dimensione minima della ferita non deve includere il viso o la zona genitale o perineale) .
    Tutte le ferite target (TW) previste devono soddisfare i seguenti criteri:
    1. Le aree SPT che non possono essere delimitate dalle aree DPT e FT devono essere inferiori al 50% della % di TBSA interessata dalla TW;
    2. Le vescicole delle ferite possono essere rimosse/aperte, secondo il giudizio dello sperimentatore.
    E.4Principal exclusion criteria
    Exclusion Criteria- Patient level
    1. Patients who are unable to follow study procedures and follow up period,
    2. Modified Baux index14 = 80,
    3. Patients with burned charred fingers, 3rd degree in depth and possibly devoid of circulation,
    4. Patients with abraded wound/s that cannot be treated by an enzymatic debrider application (NexoBrid) will be excluded from the study,
    5. Patients with electrical or chemical burns,
    6. Patients with circumferential (= 80% of the limb circumference) DPT and/or FT burns defined as Extremities at Risk (EAR) as described in section 11.8,
    7. The following pre-enrollment dressings: a. Flammacerium, b. Silver Nitrate (AgNO3),
    8. Patients with pre-enrolment wounds which are covered by eschar heavily saturated with iodine or by SSD pseudoeschar (e.g. pseudoeschar as a result of >12 h SSD treatment),
    9. Patients with pre-enrollment escharotomy,
    10. Patients with diagnosed infections as described in Section 11.9 of study protocol,
    11. Diagnosis of smoke inhalation injury,
    12. Pregnant women (positive pregnancy test) or nursing mothers,
    13. Poorly controlled diabetes mellitus (HbA1c>11%) in patients with known diabetes as captured in the medical history,
    14. BMI greater than 39.0 kg/m2 in patients with burns area of up to 15% TBSA or BMI greater than 34.0 kg/m2 in patients with burns area of more than 15% %TBSA,
    15. ASA greater than 2 (Appendix 13- ASA classification system),
    16. Cardio-pulmonary disease (MI within 6 months prior to injury, severe pulmonary hypertension,
    severe COPD or pre-existing oxygen-dependent pulmonary diseases, severe broncho-pneumonia within 1 month prior to injury, steroid dependent asthma or uncontrolled asthma),
    17. Pre-existing diseases which interfere with circulation (severe peripheral vascular disease, severe edema and/or lymphedema, regional lymph nodes dissection, significant varicose veins),
    18. Any conditions that would preclude safe participation in the study or adding further risk to the basic acute burn trauma (such as severe immuno-compromising diseases, life threatening trauma, severe pre-existing coagulation disorder, severe cardiovascular disorder, significant pulmonary disorder, significant liver disorder including post alcoholic abuse impaired function or neoplastic disease, blast injury),
    19. Chronic systemic steroid intake,
    20. History of allergy and/or known sensitivity to pineapples, papaya, Bromelain or papain,
    21. Current (within 12 months prior to screening) suicide attempt,
    22. Mentally incapacitated adults who are incapable of giving legal consent
    23. Enrollment in any investigational drug trial within 4 weeks prior to screening,
    24. Current (within 12 months prior to screening) severe alcohol or drug use disorder (see Definition in section 1.1),
    25. Prisoners and incarcerated,
    26. Patients who might depend on the clinical study site or investigator.
    Criteri di esclusione - Livello paziente
    1. Pazienti non in grado di seguire le procedure dello studio e il periodo di follow-up;
    2. Indice di Baux modificato = 80;
    3. Pazienti con dita bruciate, carbonizzate, di 3o grado di profondità ed eventualmente prive di circolazione;
    4. Pazienti con ferita/e abrasa/e che non può/possono essere trattata/e con l'applicazione di un agente di sbrigliamento enzimatico (NexoBrid);
    5. Pazienti con ustioni elettriche o chimiche;
    6. Pazienti con ustioni DPT e /o FT circonferenziali (> 80% della circonferenza dell'arto) definite come Estremità a Rischio (EAR), come descritto nella sezione 11.8;
    7. Pazienti sottoposti prima dell'arruolamento alle seguenti medicazioni: a. Flammacerium, b. Nitrato d'argento (AgNO3),
    8. Pazienti con ferite pre-arruolamento coperte da escara fortemente satura con iodio o da pseudoescara SSD (ovvero, pseudoescara conseguente a trattamento SSD > 12 ore);
    9. Pazienti sottoposti ad escarotomia prima dell'arruolamento;
    10. Pazienti con infezioni diagnosticate come descritto nella sezione 11.9 del protocollo di studio;
    11. Diagnosi di lesione per inalazione di fumo;
    12. Donne incinte (test di gravidanza positivo) o in allattamento;
    13. Diabete mellito scarsamente controllato (HbA1c> 11%) in pazienti affetti da diabete noto presente nell'anamnesi;
    14. IMC maggiore di 39,0 kg/m2 in pazienti con aree ustionate fino al 15% della TBSA o IMC maggiore di 34,0 kg/m2 in pazienti con aree ustionate superiori al 15% della TBSA;
    15. L'ASA superiore a 2 (vedi Appendice 13 nel protocollo dello studio)
    16. Malattie cardio-polmonari (MI nei 6 mesi precedenti al trauma, grave ipertensione polmonare, BPCO grave o malattie polmonari ossigeno-dipendenti preesistenti, grave broncopolmonite entro 1 mese prima del trauma, steroidi asma dipendente o asma non controllata),
    17. Le condizioni note che interferiscono con la circolazione (la malattia vascolare periferica, l'edema, la linfedema, la chirurgia ai
    linfonodi regionali e significative vene varicose),
    18. Le eventuali condizioni note che potrebbero precludere la partecipazione sicura allo studio o aggiungere l'ulteriore rischio alla
    base del trauma dell'ustione acuta (così come le malattie immuno-compromesse, i traumi in pericolo di vita, i disturbi della
    coagulazione pre-esistente grave, pulmono-cardiovascolare, la malattia del fegato o neoplastica),
    19. L'assunzione cronica di steroidi sistemici,
    20. Storia di allergia e/o sensibilità nota all'ananas, alla papaia, alla Bromelina o alla papaina,
    21.Tentativo di suicidio corrente (entro 12 mesi prima dello screening),
    22. adulti mentalmente incapaci che non sono in grado di dare il consenso legale,
    23. L'arruolamento in qualsiasi sperimentazione di farmaco in studio/sperimentale entro 4 settimanw prima dello screening,
    24. Attuale abuso (entro 12 mesi prima dello screening) di alcolo abuso di droghe (definizione nella sezione 1.1) ,
    25. Prigionieri e incarcerati,
    26. Pazienti che potrebbero dipendere dal luogo dello studio clinico o dallo sperimentatore.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint will be investigated at a "per patient" level:
    Incidence of complete eschar removal: Demonstrate superiority over Gel Vehicle for eschar removal as measured by incidence of complete eschar removal assessed by the blinded assessor at the end of the topical agent soaking period (6 hours after start of the 1st topical application).
    Or, in cases where 2 applications are performed, complete ER is assessed 6 hours after start of the 2nd Treatment.
    E.5.1.1Timepoint(s) of evaluation of this end point
    End of the topical agent soaking period.
    E.5.2Secondary end point(s)
    The following secondary endpoints will be evaluated in this study and compared between NexoBrid and SOC.
    1. Reduction in surgical need- Demonstrate superiority of NexoBrid over SOC in reduction of surgical need for excisional eschar removal as measured by an analysis of incidence of surgical eschar removal (tangential/ minor/ avulsion/ Versajet and/or dermabrasion excision).
    2. Earlier eschar removal- Demonstrate superiority of NexoBrid over SOC in reduction of the time to achieve complete eschar removal.
    3. Blood loss- Demonstrate superiority of NexoBrid over SOC with regard to the blood loss incurred during the eschar removal procedures

    Safety Endpoints
    The following group of safety endpoints will be evaluated in this study and compared between NexoBrid and SOC. These endpoints are used to ensure that NexoBrid does not cause an unacceptable level of harm.
    1. Time to reach complete wound closure assessed in days, starting from randomization date. Demonstrate that NexoBrid does not cause any clinically meaningful harm to the patients with respect to the wound healing process by comparing NexoBrid mean time to wound closure with SOC mean time to wound closure, where a difference of not more than 7 days difference will be interpreted as clinically not relevant.
    2. Cosmesis and function at 12 months from wound closure - A measure of cosmesis, using MVSS, will be used to demonstrate - that treatment with NexoBrid does not cause any clinically meaningful deleterious effect on scars quality as compared to scars quality of burns treated with SOC, measured at 12 months from wound closure date, by a blinded assessor. Clinically meaningful deleterious effect will be defined as a NexoBrid group mean MVSS score higher by 1.9 or more units than the SOC group mean MVSS score.
    3. Cosmesis and function at 24 months from wound closure - A measure of cosmesis, using MVSS, will be used to demonstrate that Treatment with NexoBrid does not cause any clinically meaningful deleterious effect on scars quality as compared to scars quality of burns treated with SOC, measured at 24 months from wound closure date, by a blinded assessor. Clinically meaningful deleterious effect will be defined as a NexoBrid group mean MVSS score higher by 1.9 or more units than the SOC group mean MVSS score.
    The following secondary endpoints will be evaluated in this study and compared between NexoBrid and SOC.
    1. Reduction in surgical need- Demonstrate superiority of NexoBrid over SOC in reduction of surgical need for excisional eschar removal as measured by an analysis of incidence of surgical eschar removal (tangential/ minor/ avulsion/ Versajet and/or dermabrasion excision).
    2. Earlier eschar removal- Demonstrate superiority of NexoBrid over SOC in reduction of the time to achieve complete eschar removal.
    3. Blood loss- Demonstrate superiority of NexoBrid over SOC with regard to the blood loss incurred during the eschar removal procedures

    Safety Endpoints
    The following group of safety endpoints will be evaluated in this study and compared between NexoBrid and SOC. These endpoints are used to ensure that NexoBrid does not cause an unacceptable level of harm.
    1. Time to reach complete wound closure assessed in days, starting from randomization date. Demonstrate that NexoBrid does not cause any clinically meaningful harm to the patients with respect to the wound healing process by comparing NexoBrid mean time to wound closure with SOC mean time to wound closure, where a difference of not more than 7 days difference will be interpreted as clinically not relevant.
    2. Cosmesis and function at 12 months from wound closure - A measure of cosmesis, using MVSS, will be used to demonstrate - that treatment with NexoBrid does not cause any clinically meaningful deleterious effect on scars quality as compared to scars quality of burns treated with SOC, measured at 12 months from wound closure date, by a blinded assessor. Clinically meaningful deleterious effect will be defined as a NexoBrid group mean MVSS score higher by 1.9 or more units than the SOC group mean MVSS score.
    3. Cosmesis and function at 24 months from wound closure - A measure of cosmesis, using MVSS, will be used to demonstrate that Treatment with NexoBrid does not cause any clinically meaningful deleterious effect on scars quality as compared to scars quality of burns treated with SOC, measured at 24 months from wound closure date, by a blinded assessor. Clinically meaningful deleterious effect will be defined as a NexoBrid group mean MVSS score higher by 1.9 or more units than the SOC group mean MVSS score.; I seguenti endpoint secondari saranno valutati in questo studio e confrontati tra NexoBrid e SOC.
    1. Riduzione della chirurgia -dimostrare la superiorit¿ di NexoBrid rispetto al SOC nella riduzione della necessit¿ chirurgica per la rimozione dell'escara come misurato da un'analisi di incidenza della rimozione chirurgica dell'escara (tangenziale / minore / avulsione / Versajet e / o la dermoabrasione escissione).
    2. prematura eliminazione dell'escara- dimostrare la superiorit¿ di NexoBrid rispetto al SOC nella riduzione del tempo necessario ad ottenere la rimozione completa dell'escara.
    3. Perdita di sangue: dimostrare la superiorit¿ di NexoBrid rispetto al trattamento SOC per quanto riguarda la perdita di sangue subita durante le procedure di rimozione dell'escara.
    Endpoint di sicurezza
    In questo studio sar¿ valutato confrontato tra NexoBrid e il SOC il seguente gruppo di endpoint di sicurezza. Questi endpoint vengono utilizzati per confermare che NexoBrid ha un effetto deleterio inferiore.
    1. Tempo richiesto per raggiungere la completa cicatrizzazione delle ferite, valutato in giorni a partire dalla randomizzazione.
    2. Estetica e funzionalit¿: saranno misurate utilizzando la scala MVSS per dimostrare che il trattamento con NexoBrid non ha alcun effetto deleterio clinicamente significativo sulla qualit¿ delle cicatrici di ustioni rispetto alla qualit¿ delle cicatrici di ustioni trattate con il SOC. L'endpoint sar¿ valutato mediante misurazioni a 12 mesi dalla data di cicatrizzazione della ferita da un valutatore in cieco;
    3. Estetica e funzionalit¿: saranno misurate utilizzando la scala MVSS per dimostrare che il trattamento con NexoBrid non ha alcun effetto deleterio clinicamente significativo sulla qualit¿ delle cicatrici di ustioni rispetto alla qualit¿ delle cicatrici di ustioni trattate con il SOC. L'endpoint sar¿ valutato mediante misurazioni a 24 mesi dalla data di cicatrizzazione della ferita da un valutatore in cieco.
    E.5.2.1Timepoint(s) of evaluation of this end point
    -time when complete eschar removal has been achieved.
    - time when complete wound closure has been achieved
    -12 and 24 months following to the confirmatory wound closure visit
    -time when complete eschar removal has been achieved.
    - time when complete wound closure has been achieved
    -12 and 24 months following to the confirmatory wound closure visit; -Momento in cui la completa rimozione dell'escara ¿ stata raggiunta.
    - Momento in cui la completa chiusura della ferita ¿ stata raggiunta
    -12 e 24 mesi dopo la visita di conferma di chiusura della ferita
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenicity
    Immunogenicit¿
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind Yes
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Standard di cura
    Standard of Care
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA10
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Israel
    United States
    Belgium
    Czechia
    Germany
    Italy
    Romania
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 170
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 5
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2021-01-13. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state15
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 80
    F.4.2.2In the whole clinical trial 175
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients are treated according to standard of care after end of participation in the trial.
    I pazienti sono trattati secondo lo Standard di Cura dopo la fine della partecipazione allo studio clinico.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-11-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-11-25
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA